Lucinactant for Treatment of Acute Hypoxemic Respiratory Failure in Children up to Two Years Old

Completed · Phase 2 · Has a placebo group

Conditions studied: Acute Hypoxemic Respiratory Failure

In brief

Treatment with lucinactant, a peptide-containing synthetic lung surfactant, will be evaluated in young children with acute respiratory failure who require mechanical ventilation (life support), to determine if it is safe and if treatment with lucinactant will reduce the number of days a child needs mechanical ventilation (life support).

Key facts

Study ID
NCT00578734
Run by
Windtree Therapeutics
People needed
165
Starts
2007-06-01
Expected to finish
2010-04-01
Last updated by the study team
2012-05-03

Who can join

Age: any, up to 2. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.